What Is Frozen Shoulder — and Will It Actually Thaw?

What Is Frozen Shoulder?

Frozen shoulder — formally termed adhesive capsulitis — is a condition characterised by progressive pain and stiffness in the glenohumeral (shoulder) joint, caused by inflammation and fibrosis of the joint capsule. The shoulder capsule, which normally forms a loose, compliant sleeve around the joint, becomes thickened, contracted, and adherent — restricting movement in all directions but particularly external rotation, abduction, and behind-back internal rotation. It is one of the most painful and protracted musculoskeletal conditions, with natural history studies reporting duration of one to three years without treatment — though this estimate represents the full untreated course, and most cases respond meaningfully to appropriate intervention.

The Three Stages

Frozen shoulder classically progresses through three overlapping clinical stages. The freezing stage (pain-dominant, lasting two to nine months) is characterised by insidious onset of deep aching shoulder pain, often worst at night and with reaching movements, with progressive loss of movement as the capsular inflammation intensifies. The pain at this stage can be severe — disproportionate to the apparent mechanical restriction — reflecting the dense nociceptive innervation of the inflamed capsule. The frozen stage (stiffness-dominant, lasting four to twelve months) sees pain begin to plateau and partially resolve, but marked restriction of movement persists as the fibrotic capsular contracture dominates. Activities of daily living — reaching overhead, behind the back, and across the body — are severely limited. The thawing stage (resolution, lasting five to twenty-four months) involves gradual spontaneous recovery of movement as the capsular fibrosis remodels.

Who Gets Frozen Shoulder?

Frozen shoulder has a population incidence of approximately 2–5%, predominantly affecting individuals between 40 and 65 years of age, with women affected more frequently than men (approximately 3:2 ratio). The most significant systemic risk factor is diabetes mellitus — diabetic individuals have a five- to ten-fold increased risk, more severe presentation, longer duration, and higher rates of bilateral involvement. Thyroid dysfunction (both hypo- and hyperthyroidism), Parkinson's disease, and prolonged shoulder immobilisation (post-fracture, post-surgery, or from prolonged sling use) are additional risk factors. Approximately 50% of cases occur without an identifiable precipitant — so-called idiopathic adhesive capsulitis.

Why Does the Capsule Freeze?

The pathological process begins with synovial inflammation in the capsule — cytokine-mediated (particularly IL-1, TNF-α, and TGF-β) inflammatory cell infiltration that drives the initial pain phase. The transition to fibrosis is mediated by TGF-β stimulating fibroblast-to-myofibroblast differentiation — the same cell type responsible for pathological fibrosis in other tissues — producing excessive collagen deposition and contracture of the capsule. The rotator interval (the capsular region between the supraspinatus and subscapularis tendons) and the axillary recess are the most consistently affected areas, and loss of volume in these regions directly corresponds to the clinical movement restrictions observed. In diabetic individuals, advanced glycation end-products (AGEs) promote collagen cross-linking and reduce tissue remodelling capacity, explaining the more severe and prolonged presentations in this population.

Evidence-Based Management

In the painful freezing stage, management prioritises pain control and maintaining available range — aggressive stretching is counterproductive and worsens inflammation. Corticosteroid injection into the glenohumeral joint provides the most evidence-supported short-term (6-week) pain reduction and movement improvement, enabling engagement with rehabilitation. Gentle pendulum exercises and pain-free passive range of motion preserve movement gains. In the frozen stage, progressive manual therapy — capsular stretching, glenohumeral mobilisation, and soft tissue release of the pericapsular muscles — combined with active range of motion exercise drives gradual recovery. Hydrodilatation (injection of saline under pressure to distend the contracted capsule) has evidence for accelerating range recovery in refractory cases. Physiotherapy supervised shoulder stretching in the thawing stage consolidates the natural recovery and accelerates full return of function.

Will It Fully Resolve?

The majority of frozen shoulder cases — approximately 60–90% in different study populations — do achieve full or near-full resolution of both pain and movement with time and appropriate treatment, though this process takes considerably longer than most patients hope. A minority (estimated 10–40% depending on the study and population) retain some persistent movement restriction or recurrent discomfort, particularly in the diabetic population. Early treatment — particularly corticosteroid injection in the freezing stage and structured rehabilitation through the frozen and thawing stages — substantially reduces total duration and disability compared to watchful waiting. The prognosis for non-diabetic idiopathic frozen shoulder is excellent with appropriate care.